Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 176

  • 3 901 clinical trials
  • 1 548 recruiting
  • 705 conditions
  • 31 countries

Conditions in this area

705 conditions with trials, the busiest first

Non-small cell lung cancer327Breast cancer168Plasma cell myeloma165Neoplasm158Acute myeloid leukaemia132Neoplasm malignant128Colorectal cancer metastatic105Prostate cancer101Ovarian cancer91Colorectal cancer89Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Malignant melanoma79Chronic lymphocytic leukaemia77Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV57Pancreatic carcinoma57Hormone-refractory prostate cancer56Bladder cancer55Gastric cancer55Endometrial cancer53+681

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 901 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 901 clinical trials

Waldenstrom's macroglobulinaemia+1

Not recruiting

Evaluating Sonrotoclax Alone and Combined with Zanubrutinib for Patients with Previously Untreated or Relapsed/Refractory Waldenström Macroglobulinemia

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Zanubrutinib
  • Sponsor:BeOne Medicines AG

Squamous cell carcinoma of head and neck

Not recruiting

Study of pucotenlimab with becotatug vedotin versus becotatug vedotin alone for patients with locally advanced head and neck squamous cell carcinoma

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pucotenlimab
  • Sponsor:Groupe Oncologie Radiotherapie Tete Cou

Small cell lung cancer

Not recruiting

Study of Tarlatamab Treatment in Patients with Small Cell Lung Cancer: Evaluation of Different Dosing Schedules

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Siltuximab
  • Sponsor:Amgen Inc.

Glioblastoma+1

Not recruiting

Study on the Safety of Photodynamic Therapy with Aminolevulinic Acid Hydrochloride for Patients Aged 18-75 with Grade IV Glioblastoma

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Aminolevulinic Acid Hydrochloride
  • Sponsor:Hemerion Therapeutics

Breast cancer in situ+1

Not recruiting

Study on Breast Cancer Prevention in High-Risk Women Using Low Dose Tamoxifen and Lifestyle Changes

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Tamoxifen Citrate
  • Sponsor:Istituto Europeo Di Oncologia S.r.l.

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study on the Effects of Ribociclib and Endocrine Therapy for Patients with HR-Positive, HER2-Negative Early Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Novartis Pharma AG

Bladder transitional cell carcinoma

Not recruiting

Study on the Effectiveness of Durvalumab and BCG in Treating High-Risk, Non-Muscle Invasive Bladder Cancer in Patients New to BCG Treatment

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Neoplasm+1

Not recruiting

Study on Niraparib and Dostarlimab for Patients with DNA Repair-Deficient or Platinum-Sensitive Solid Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Dostarlimab
  • Sponsor:Institut Gustave Roussy

Breast cancer+2

Not recruiting

Study on Denosumab to Prevent Breast Cancer in Women with BRCA1 Mutation

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · Healthy volunteers
  • Substances:Denosumab
  • Sponsor:ANZ Breast Cancer Trials Group Limited

Philadelphia positive chronic myeloid leukaemia

Not recruiting

Study on the Bioavailability of Nilotinib in Healthy Individuals with Chronic Myelogenous Leukemia (CML)

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · Healthy volunteers
  • Substances:Nilotinib
  • Sponsor:Bluepharma Industria Farmaceutica S.A.

Prostate cancer

Not recruiting

Study on Sildenafil and Vacuum Erection Device Therapy for Men with Prostate Cancer Undergoing Nerve-Sparing Surgery

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Sildenafil
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Plasma cell myeloma

Not recruiting

Study on the Safety and Effectiveness of Anitocabtagene Autoleucel and Drug Combination for Patients with Newly Diagnosed Multiple Myeloma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Fundacion PETHEMA

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Pembrolizumab463 clinical trialsCarboplatin340 clinical trialsCisplatin285 clinical trialsPaclitaxel263 clinical trialsFluorouracil237 clinical trialsOxaliplatin227 clinical trialsNivolumab217 clinical trialsDexamethasone169 clinical trialsDurvalumab163 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.